SSA
INO icon

Schonfeld Strategic Advisors’s Inovio Pharmaceuticals INO Stock Holding History

Schonfeld Strategic Advisors’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-8,974
Closed -$48.1K – 2005
2023
Q2 		$48.1K Buy
+8,974
New +$72.3K ﹤0.01% 1814
2023
Q1 		– Sell
-15,498
Closed -$290K – 2344
2022
Q4 		$290K Sell
15,498
-8,129
-34% -$184K ﹤0.01% 1815
2022
Q3 		$489K Buy
23,627
+13,385
+131% +$343K ﹤0.01% 1768
2022
Q2 		$213K Buy
10,242
+9,325
+1,017% +$263K ﹤0.01% 1853
2022
Q1 		$40K Sell
917
-2,208
-71% -$99.5K ﹤0.01% 2363
2021
Q4 		$187K Buy
3,125
+1,225
+64% +$98.1K ﹤0.01% 1766
2021
Q3 		$163K Sell
1,900
-2,713
-59% -$272K ﹤0.01% 1826
2021
Q2 		$513K Buy
+4,613
New +$443K 0.01% 1181
2021
Q1 		– Sell
-8,870
Closed -$942K – 1954
2020
Q4 		$942K Buy
8,870
+8,025
+950% +$1.07M 0.01% 835
2020
Q3 		$118K Buy
+845
New +$176K ﹤0.01% 1257

Other funds holding INO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Schonfeld Strategic Advisors's INO Position: Q3 2023 in Review

Schonfeld Strategic Advisors sold out of Inovio Pharmaceuticals (INO) in Q3 2023, closing a stake of 8,974 shares — an estimated $48.1K sold.

Schonfeld Strategic Advisors first reported a position in INO in Q3 2020 and held it in 10 quarters. The position peaked at $942K in Q4 2020. 124 funds tracked by Wall St. Rank hold INO as of Q3 2023.

  • Schonfeld Strategic Advisors reported no remaining Inovio Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 8,974 Inovio Pharmaceuticals shares in Q3 2023, an estimated $48.1K.
  • Schonfeld Strategic Advisors first reported a position in Inovio Pharmaceuticals in Q3 2020 and held it in 10 quarters.
  • Schonfeld Strategic Advisors's Inovio Pharmaceuticals position peaked at $942K in Q4 2020.
  • 124 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q3 2023.

Based on Schonfeld Strategic Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.